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Molecular changes occurring during invasion and clinical progression of cancer are difﬁcult to study longitudinally in patient-
derived material. A unique feature of urothelial bladder cancer (UBC) is that patients frequently develop multiple nonmuscle
invasive tumors, some of which may eventually progress to invade the muscle of the bladder wall. Here, we use a cohort of
73 patients that experienced a total of 357 UBC diagnoses to study the stability or change in detected molecular alterations
during cancer progression. The tumors were subtyped by gene expression proﬁling and analyzed for hotspot mutations in
FGFR3, PIK3CA and TERT, the most frequent early driver mutations in this tumor type. TP53 alterations, frequent in advanced
UBC, were inferred from p53 staining pattern, and potential genomic alterations were inferred by gene expression patterns at
regions harboring frequent copy number alterations. We show that early driver mutations were largely preserved in UBC
recurrences. Changes in FGFR3, PIK3CA or TERT mutation status were not linked to changes in molecular subtype and
aggressive behavior. Instead, changes into a more aggressive molecular subtype seem to be associated with p53 alterations.
We analyze changes in gene expression from primary tumors, to recurrences and progression tumors, and identify two modes
of progression: Patients for whom progression is preceded by or coincides with a radical subtype shift, and patients who
progress without any systematic molecular changes. For the latter group of patients, progression may be either stochastic or
depending on factors already present at primary tumor initiation.
Introduction
Surface epithelia are composed of clonal areas that replenish
the tissue during normal homeostasis.1–3 Recurrent in situ
and papillary lesions occurring in these tissues within the
same patient are either independent, originating from differ-
ent clonal units or may have a shared clonal origin. If the site
of tumor recurrence is different from that of the primary
tumor, this is a manifestation of ﬁeld cancerization,4 either
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due to single clone expansion or due to independent ﬁelds, that
is, oligo-clonal acquisition of tumor-initiating capacity.5 Studies
on the genetic heterogeneity of the premalignant ﬁeld in
patients with urothelial bladder cancer (UBC) have given
important insights into the processes behind tumor initiation
and favor a clonal origin.6–9 The shared clonal origin of
nonmuscle invasive bladder cancer (NMIBC) recurrences has
been repeatedly demonstrated10–12 even though tumors usually
occur in different locations within the bladder.13 Taken
together, a model is supported in which tumors develop semi-
independently out of a premalignant ﬁeld that is usually clonal
in nature but has additional heterogeneity that manifests as
genetic differences between recurrences.14,15 Thus, NMIBC is
an ideal system to study the stability of molecular characteris-
tics in multiple local recurrences originating from the same pre-
malignant epithelium. In clinical management, the least
aggressive forms of NMIBC (Ta, low-grade) are lacking inva-
sive potential even without resection.16 On the other hand
recurrences frequently occur, also in patients with low-grade
tumors, many experiencing over 10 recurrences over the course
of many years.17,18 The risk of progression to muscle-invasive
bladder cancer (MIBC) and cancer-speciﬁc death for these
patients is minimal but increases to 18% when including stage
T1 high-grade disease.19 High-risk NMIBC patients are treated
with intravesical Bacillus Calmette-Guerin (BCG) or even radi-
cal cystectomy (RC). Predictors of increased risk include patho-
logical stage T1, high pathological grade,20 molecular risk
scores21,22 and an aggressive, Genomically Unstable or Basal/
Squamous, molecular subtype.23 Recurrent as well as progres-
sive disease has also been studied longitudinally in clinical17,24
and molecular studies.11,18,25,26 However, the proportion of
patients that progress in these existing studies is low. Therefore,
they do not fully capture the variability between the patients
and tumors that eventually progress. This knowledge gap poses
a problem when data from one single index tumor is selected
as a basis for risk prediction at the patient-level.
The aim of our study was to use recurrent NMIBC as a
model system to study the longitudinal stability or change in
molecular subtypes and driver mutations of recurrent tumors
arising in the same epithelial tissue. We correlate the ﬁndings
with the patient’s clinical history, the timing of recurrences
and intravesical treatment courses. We add a new perspective
compared to previous studies11,18,25,26 by studying exclusively
the population that eventually progress to advanced disease.
Materials and Methods
Patient and tumor characteristics
We identiﬁed 73 patients treated for a primary NMIBC
between 1989 and 2013 in seven hospitals in the Southern
Health Care region in Sweden that subsequently developed
NMIBC recurrences, and ﬁnally progressed. Progression was
deﬁned as a diagnosis of MIBC, metastasis (M+) or that the
patient underwent RC. Our study thus adheres to established
deﬁnitions,27 except that we did not consider an increase in
tumor stage from Ta/CIS to T1 or an increase in grade to con-
stitute a progression event. The study was approved by the
local ethical review board. Pathological review was performed
by an experienced uropathologist (GC) using the WHO 1999
grading system. The 73 patients presented with 357 tumors,
with a minimum of two, a maximum of 17 and a median of
four tumors per patient. The majority (45/73, 62%) of the
patients received at least one full induction course of
intravesical BCG, and a minority (7/73, 10%) received
intravesical chemotherapy regimens (full courses of
Mitomycin-C or Epirubicin). The advent of BCG in favor of
instillations with chemotherapy and the introduction of re-
resection in TaG3/T1-disease were successively applied
according to hospital routines, until the ﬁrst national bladder
cancer guidelines were published in 2013. Data and timing of
tumor stage, tumor grade, intravesical treatment and type of
progression are summarized in Figures 1a and 1b. Clinical
data are available in Supporting Information Table S1.
Immunohistochemistry
From the 357 tumors, 300 formalin-ﬁxed parafﬁn-embedded
(FFPE) transurethral resection of bladder tumor (TUR-BT) tis-
sue blocks were obtained of which 271 contained sufﬁcient
tissue for immunohistochemistry (IHC)-based molecular clas-
siﬁcation. For each TUR-BT, one tissue block from a single
tumor was used for all molecular analyses. Tumors were
embedded in tissue microarrays (TMAs) with two 1.0 mm
cores per tumor, although for 46 tumors only a single TMA
core was available. Hematoxylin and Eosin staining, and IHC
against 16 proteins were applied (CCNB1, CNND1, CDH1,
EPCAM, ERBB2 FGFR3, FOXA1, GATA3, KRT14, KRT5,
p16, RB1, p53, TUBB2B, VIM and ZEB2; Supporting Informa-
tion Table S2). IHC-based molecular subtype classiﬁcation was
performed by calculating 4-marker subtype scores as described
previously,28 using prespeciﬁed cut-offs for class assignment.
Brieﬂy, basal/squamous-like (Ba/Sq) subtype was assigned to
What’s new?
Molecular changes occurring during invasion and clinical progression of cancer are difﬁcult to study longitudinally in patient-
derived material. A unique feature of urothelial bladder cancer is that patients frequently develop multiple nonmuscle invasive
tumors, some of which may eventually progress to invade the muscle of the bladder wall. Here, the authors perform multi-level
longitudinal analyses on patients with progression from non-muscle invasive to advanced disease and describe novel modes of
progression related to shifts in molecular proﬁles. Combined with the theory of ﬁeld cancerization, these results identify
limitations in predicting clinical progression based on molecular data from non-muscle invasive tumors.
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tumors with high KRT5, KRT14 and low FOXA1, GATA3.
Mesenchymal-like (Mes-like) subtype was assigned to tumors
with high VIM, ZEB2 and low CDH1, EPCAM. Small-cell/
neuroendocrine-like (Sc/NE) subtype was assigned to tumors
with high EPCAM, TUBB2B and low CDH1, GATA3. Tumors
not assigned to either of these three subtypes are “Luminal-
like” and were further classiﬁed as Urothelial-like (Uro) if
CCND1, FGFR3 and RB1 showed strong and p16 weak
staining, or genomically unstable (GU) if they showed the
opposite staining intensities. Thus, the ﬁve subtype scores rep-
resent condensed molecular data points, each contributing
information essential for assessing the tumor phenotype. We
considered patients to have stable subtypes if each tumor had
an internal correlation of subtype scores >0.75 compared to
the mean subtype scores of the patient. The cut-off was applied
as a quality control to ensure that subsequent analyses were
based on robust subtype shifts and not merely nominal
changes due to a threshold effect in classiﬁcation. The cut-
point was selected empirically, prior to analyses, and is data set
speciﬁc. IHC data were manually inspected to ensure that
substantial subtype shifts were not excluded in this process. All
IHC data are available in Supporting Information Table S1.
Transcriptomics and RNA-based molecular subtype
classiﬁcation
Tumor areas were macrodissected from FFPE sections, RNA
was extracted and 200 tumors were analyzed using Affymetrix
Gene ST 1.0 microarrays. Macrodissection and extraction
protocols were as described previously.28 Samples with a total
RNA yield of 0.5 μg or more were ampliﬁed, labeled
(SensationPlus kit, Thermo Fisher, Waltham, MA) and hybrid-
ized to Gene ST 1.0 arrays (Thermo Fisher). The data set was
preprocessed by RMA-normalization followed by COMBAT
adjustment of labeling batches, and median centered for
heatmap visualization. Molecular subtype classiﬁcation was per-
formed into the Lund Taxonomy subtypes described
previously,29 by classifying single-samples into the main molec-
ular subtypes Uro, GU, Ba/Sq, Mes-like and Sc/NE and the sub-
classes UroA, UroB and UroC, for samples ﬁrst classiﬁed as
Uro. The consensus molecular subtypes of MIBC were also
applied.30 Molecular classiﬁcation results are available in
Supporting Information Table S1.
Mutation analysis
We used DNA from FFPE extractions of 220 tumors to perform
a battery of 15 snapshot assays to detect the nine most frequent
mutations in FGFR3, the three most frequent mutations in
PIK3CA, and the three most frequent mutations in the TERT
promoter. The assays have been described and validated
previously,31–33 and mutation calling based on chromatogram
peaks was done blinded to the identity of the samples. DNA
extraction yield ranged from 0.1 to 17.1 μg, and showed weak
association with the number of detected mutations (Supporting
Information Table S3). Only tumors with an unambiguous peak
indicating the clear presence of a mutant allele were annotated
as carrying the mutation. We identiﬁed 11 low or ambiguous
Figure 1. Chronologic disease course for 73 patients with progressive UBC. Patient timelines are shown divided by median time to
progression into (a) early progressors with less than 3 years between primary tumor and progression, and (b) late progressors, with more
than 3 years to progression. Squares and circles represent tumor manifestations, whereas rectangles represent intravesical treatment
courses. Placement of symbols that would overlap due to short time between events has been adjusted minimally. [Color ﬁgure can be
viewed at wileyonlinelibrary.com]
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peaks that were considered wild-type in all analyses. Mutation
data are available in Supporting Information Table S1. To evalu-
ate TP53 aberrations we used IHC staining with the DO7
antibody (Dako, Carpinteria, CA). Expression patterns were
evaluated as wild type, overexpression, complete absence or
cytoplasmic, as previously described.34 The nonwild type catego-
ries were grouped to indicate p53 altered cases.
Statistical analyses
Statistical tests were performed using R, and statistical tests of
signiﬁcance were two-sided at an α = 0.05 unless otherwise
speciﬁed. Fisher’s exact test was used to test differences in
proportions of categorical data. Differentially expressed genes
were identiﬁed using paired t-test in Multi Experiment Viewer
(MeV), with genes showing q < 0.01 (using 1,000 permutations)
considered as signiﬁcant.
Data availability
Raw and processed gene expression data is available through
Gene Expression Omnibus under the accession number
GSE128959. All data of other types is available in Supporting
Information Table S1.
Results
Clinical course of progression
We studied the clinical course of recurring UBC by chronologi-
cally ordering the timelines of 73 patients, divided by median
time to progression into early and late progressors (Figs. 1a and
1b), and indicating tumor stage, tumor grade and intravesical
treatment. Organizing the data in this manner showed that
patients progressing to advanced disease within approximately
3 years were enriched for primary tumors that had invaded
across the basal membrane (Stage T1), whereas patients with
later progression more frequently had primary tumors conﬁned
to the urothelium (Stage Ta, p = 0.03). It also became evident that
patients with multiple low grade (G1-G2) recurrences tended to
fall into the late progression group (Fig. 1b). Only three patients
in the early progression group experienced more than one
G1–G2 tumor before progression, while 19 patients in the late
progression group did (p = 3.2 × 10−5). Although the patients
with early progression had on average fewer NMIBC recurrences
(2.0 vs. 3.6), their rate of recurrences was more than double that
of the late progression group (1.4 vs. 0.6 recurrences per year).
We observed no difference in the type of progression (MIBC, M
+ or RC) or the use of intravesical treatment in the early vs. late
progression groups.
Changes in molecular subtype classiﬁcation occur in a
subset of patients that progress
Multiple immunostaining, transcriptomic and mutation data
from every tumor for which we could obtain material of sufﬁ-
cient quality and amount showed a large overlap such that
196 tumors were covered by all three data types (Fig. 2a).
Immunohistochemistry (IHC)-based classiﬁcation of molecu-
lar subtypes (Fig. 2b) achieved a high concordance with
respect to mRNA-based subtypes (0.82, 164 of 200 cases with
concordant classiﬁcation; Fig. 2c). Discordant classiﬁcation
was mainly (23/36) observed between the two luminal-like
Figure 2. Overlap of data types and concordance between IHC- and mRNA-based molecular subtype classiﬁcation. Venn diagram in (a)
counting tumors for which IHC (green), RNA (blue) and mutation (red) data are available. All three data types overlapped for 193 tumors. (b)
The numbers of tumors classiﬁed by IHC into each of the ﬁve major UBC molecular subtypes are shown. The four IHC stains used for
subtyping are shown for a typical case of each type. The tumor used to exemplify the Urothelial-like subtype in panel b is also shown in
Supporting Information Figure S3. Barplots in (c) show the proportion of LundTax mRNA subtypes within the IHC subtypes, and the per-
subtype concordance between the two classiﬁcation methods. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
4 Molecular changes in bladder cancer progression
Int. J. Cancer: 00, 00–00 (2019) © 2019 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC
T
um
or
M
ar
ke
rs
an
d
Si
gn
at
ur
es
subtypes urothelial-like (Uro) and genomically unstable (GU),
with 15 of the tumors classiﬁed as GU by IHC and Uro by
mRNA, and 8 tumors classiﬁed as Uro by IHC and GU by
mRNA. This is in accordance with previous ﬁndings in which
UroC, a subset of Uro tumors, has been shown to be difﬁcult
to discriminate from GU.28
We ordered patients by the molecular subtype of the last
classiﬁed tumor and investigated to what extent classiﬁcation
changed over the disease course (Fig. 3). Patients for whom
the last classiﬁed tumor was of the Uro subtype tended to
have more prior tumors, almost exclusively also classiﬁed as
Uro (Fig. 3a). Since the Uro subtype contains most cases with
low stage (Ta) and grade (G1–G2) it is logical that these
patients experience more tumors before progression. In these
patients, only two recurrences were classiﬁed into a different
subtype by both IHC- and mRNA-based subtyping, that is,
very few deﬁnite subtype shifts were observed. Patients for
whom the last classiﬁed tumor was of the GU subtype tended
to have prior tumors of either the GU or the Uro subtypes
(Fig. 3b). Patients for whom the last classiﬁed tumor was of
the Basal/Squamous-like (Ba/Sq), Mesenchymal-like (Mes-
like) or Small-cell/Neuroendocrine-like (Sc/NE) subtypes, had
few prior tumors that could be of any subtype (Fig. 3c).
Although molecular subtype classiﬁcation was stable within
most patients, the assignment of one subtype to each tumor
may result in different subtype labels for tumors simply because
they are close to the threshold between two subtypes. To avoid
false interpretations of such threshold effects as subtype change,
we quantiﬁed phenotypic differences by analyzing quantitative
scores from the IHC-, and mRNA-classiﬁers. For each tumor,
we compared the values on the ﬁve subtype scores to the mean
subtype scores from the same patient. This value was used as a
similarity measure in the subtype classiﬁcation space. As shown
in Supporting Information Figure S1 this measure identiﬁes a
major group of patients for which all the tumors were internally
highly similar and a minor group of patients in which one or
several outlier tumors deviated from the rest. We consider only
the subtype changes in the latter patient category to be valid,
whereas the nominally different subtype classiﬁcations in the
stable group were disregarded as threshold effects. Thus, in the
full cohort, 20 patients (27%) had at least one subtypes change
before progression that was validated with this approach. For
seven patients, we identiﬁed valid subtype shifts both on the
IHC and mRNA level, whereas ﬁve and eight patients showed
validated shifts only at the IHC-, and mRNA levels, respectively.
Stability of driver mutations over multiple recurrences is
independent of molecular subtype
Next, we analyzed hotspot driver mutations in FGFR3, PIK3CA
and TERT in 220 tumors and detected 70 FGFR3 mutations,
32 PIK3CA mutations and 185 TERT mutations (Supporting
Information Table S4). Mutations were not enriched in primary,
recurrent, or progression tumors (Supporting Information
Fig. S2), but the frequency of FGFR3mutations was, as expected,
signiﬁcantly elevated in tumors classiﬁed as Uro (40%), and low-
est (7%) in tumors classiﬁed as GU (Supporting Information
Fig. S2B). Mutations in PIK3CA were more frequent in tumors
classiﬁed as Ba/Sq (57% vs. 13% in non-Ba/Sq) although this
proportion was based on only four of seven Ba/Sq tumors carry-
ing PIK3CA mutations. Mutations in TERT were not associated
Figure 3. Changes in molecular subtype classiﬁcation in primary,
recurrent and progressive bladder tumors. Each row represents one
patient and each split box represents a tumor: The upper half
colored by the IHC-based molecular subtype and the lower half
colored by the mRNA-based subtype. The data is organized into (a)
patients for whom the last available tumor is classiﬁed as Urothelial-
like (Uro) by IHC, (b) patients for whom the last available tumor is
classiﬁed as GU by IHC and (c) patients for whom the last available
tumor is classiﬁed as basal/squamous-like (Ba/Sq), mesenchymal-
like (Mes-like) or small-cell/neuroendocrine-like (Sc/NE) by IHC.
[Color ﬁgure can be viewed at wileyonlinelibrary.com]
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with subtype (Supporting Information Fig. S2B). Tumor purity
scores, calculated using the ESTIMATE tool,35 were associated
with FGFR3, but not PIK3CA or TERT mutations, which could
be explained by a positive association between the Uro subtype
and tumor purity (Supporting Information Table S3). In longi-
tudinal analyses, a third of the patients with mutation data from
more than one tumor (23/65, 35%) had identical mutation sta-
tus in all tumors (Fig. 4a). An additional 25% (16/65) differed
by a single mutation compared to the other tumors from the
same patient. Longitudinal analyses also revealed that changes
in molecular subtype were not associated with changes in muta-
tion status of these genes. Of the tumors that changed molecular
subtype and had available mutation data, 52% (12/23) had iden-
tical mutation status to the last prior tumor, 39% (9/23) differed
in the status of a single mutation and only two of 23 (9%) dif-
fered by more than one mutation (Supporting Information
Table S5). To exemplify the various observed scenarios,
Figure 4b shows one patient with four phenotypically stable Uro
Figure 4. Mutations in recurrences are independent of molecular subtype stability. Each row in (a) represents a patient and each split box
represents a tumor: the upper third is colored by FGFR3 mutation status, the middle third by the PIK3CA mutation status and the lower third
by the TERT mutation status. Patients and tumors are organized as in Figure 3. (b) Molecular data for a patient with four tumors stably
classiﬁed as Urothelial-like (UroA–UroA–UroA–UroB), for which every tumor’s mutation status differs from the rest. (c) Molecular data for a
patient with a primary UroA tumor that changed subtype to basal/squamous in the progression tumor. The two tumors showed different
FGFR3 and PIK3CA mutations. (d) Molecular data for a patient with a primary GU tumor that changed subtype to Basal/Squamous in the
progression tumor. The two tumors showed identical mutation proﬁle. [Color ﬁgure can be viewed at wileyonlinelibrary.com]
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tumors with different mutation status in every tumor. A second
patient with a change in subtype from Uro to Ba/Sq, demon-
strated different mutation status in both FGFR3 and PIK3CA
(Fig. 4c). A third patient with a change in subtype from GU to
Ba/Sq, had identical mutation status of all three genes (Fig. 4d).
Taken together, most patients showed similar mutations in
recurrent tumors but a minor group showed highly variable
mutations. These mutation patterns did not overlap with pheno-
typic changes suggesting that they are independent.
BCG treatment and changes in molecular subtype
classiﬁcation
Therapy changes the conditions for tumor growth and may
induce change either directly or through selection. Of the
patients with a robust subtype change, 13 received BCG while
5 did not. This proportion did not differ from the patients with-
out any subtype shifts, of which 32 received BCG and 21 did not
(p = 0.41). To test the association between subtype change and
BCG at the tumor level, we counted all sequential instances of
tumors with subtype classiﬁcation data, that is, every instance
where both a subtype change and BCG treatment could have
occurred. We then classiﬁed those instances based on if a sub-
type change occurred, if BCG treatment occurred, or both. We
observed that 38% (11/29) of such instances with subtype
change coincided with BCG, compared to 21% (37/174) of
instances without subtype change (p = 0.060). Supporting Infor-
mation Table S5 lists the subtype changes and changes in muta-
tion status according to BCG treatment and progression type
(RC, MIBC or M+). To account for the fact that many patients
either did not experience any subtype shifts, or did not receive
any BCG, we repeated the tumor level analysis only in the
18 patients that experienced a subtype change (11/29 coinciding
vs. 4/27 not coinciding, p = 0.072), and also in the 13 patients
who both experienced subtype change and received BCG (11/20
coinciding vs. 4/18 not coinciding, p = 0.052). Thus, we could
not ﬁnd any statistically robust association between BCG treat-
ment and shifts in molecular subtype.
p53 staining is consistent in recurrences but may be
abnormal upon shifts to aggressive subtypes
While FGFR3, PIK3CA and TERT are frequent drivers in early-
stage UBC (NMIBC), the most commonly mutated gene in
MIBC is TP53. The D07 p53 antibody assay that detects TP53
alterations was applied with 97% concordance between TMA-
core pairs (Supporting Information Table S6). Abnormal
p53-pattern was observed in 62 of 277 tumors (22%) with highly
signiﬁcant enrichment in the GU subtype compared to Uro
(Supporting Information Fig. S2). Within Uro, p53-altered pat-
tern was also signiﬁcantly enriched in the UroC subset com-
pared to UroA/B (p = 9 × 10−4). Longitudinally, 61% (45/69) of
patients with data from multiple tumors showed wild-type
p53-pattern in all tumors, whereas 10 patients (14%) showed
p53-abnormal pattern in all tumors, and 17 patients (25%) had
both wild-type and altered tumors. A resampling test revealed
that in this dataset p53-altered tumors were clustered among
few patients to a higher degree than what would be expected by
chance (p < 10−5). In line with this stability, there was no signiﬁ-
cant overall difference in frequency of abnormal patterns for
progression tumors (15/41, 37%), compared to primary tumors
(15/43, 35%) or recurrences (31/130, 24%). The likelihood of
p53-altered pattern was also signiﬁcantly increased if the previ-
ous tumor was p53-altered compared to what would be expected
without knowledge of prior p53-status (odds ratio = 6.9, 95%
CI: 2.8–16.9). At the patient level, there was a trend toward
positive association between the occurrence of any change in
molecular subtype and any change in p53-status (p = 0.059).
We tested the association between subtype change and
p53-status at the tumor level by comparing all sequential
tumors with both data types, that is, every instance where
both a subtype change and change in p53-status could have
occurred. We then classiﬁed those instances based on if a sub-
type change occurred, if a change in p53-status occurred, or
both. This resulted in nine instances of subtype change coin-
ciding with a change in p53-status—a signiﬁcantly higher
number than expected in the absence of an association
(p = 0.0016). In Supporting Information Figure S3, we high-
light one such patient. This patient had the longest time to
progression in the cohort due to over 10 years of remission
after BCG. The patient’s ﬁrst four tumors were FGFR3wt Ta
tumors of the Uro subtype. The ﬁrst relapse after BCG, tumor
number ﬁve, had acquired FGFR3R248C mutation, still within
the Uro phenotype. Tumors number six and eight were of
stage T1 instead of Ta, had p53 overexpression, and a molec-
ular subtype shift from Uro to GU. This case suggests hetero-
geneous origins of different tumors representing one
FGFR3wt, one FGFR3R248C and one FGFR3wt/TP53-altered
genomic state, correlating with the transition from early Ta-
Uro tumors to post relapse T1-GU tumors.
Recurrences show coordinated gene expression at loci
harboring copy number alterations
To investigate changes in gene expression during progression,
we ﬁrst focused on genes that are located in genomic regions
that harbor frequent copy number alterations. Several such
regions including 3p25 (RAF1), 6p22 (E2F3/SOX4), 9p21
(CDKN2A), 11q13 (CCND1), 12q15 (MDM2), 13q14 (RB1) and
17q13 (ERBB2) were identiﬁed, and expression of genes in these
regions was investigated. Some patients showed up or down-
regulation of blocks of genes in deﬁned genomic segments con-
sistent with a copy number alteration event occurring +/−10
genes surrounding the proposed driver gene of each region
(Supporting Information Fig. S4). We made putative copy num-
ber calls for each patient indicating one or more tumors with
gene expression proﬁles suggesting ampliﬁcation or deletion at
one of the investigated loci (Supporting Information Methods).
The data for the regions where the driver gene is known is sum-
marized in Figure 5a. For four inferred copy number alterations,
we could investigate expression also at the protein level. Protein
Sjödahl et al. 7
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levels were altered in the same direction as the predicted
copy number alteration for 100/148 cases (CDKN2A 39/50,
CCND1 17/27, RB1 27/41 and ERBB2 17/30), supporting
this approach (Fig. 5a). Most patients showed stable inferred
copy number alterations in every analyzed tumor, but for
19 patients at least one alteration differed. By integrating
this data with the longitudinal subtyping and mutation data,
two patterns of progression emerge: (i) Some patients show
no molecular difference between the progression tumor and
the earlier recurrences. This is exempliﬁed by the patient
shown in Figure 5b, with four phenotypically identical UroA
tumors that all show FGFR3 and TERT mutations as well as
inferred MDM2 ampliﬁcation. Proliferation, measured by
Cyclin B1 labeling index, was unchanged in the muscle-
invasive progression tumor. (ii) Another group of patients
showed a radical shift from a Uro-proﬁle to a more aggres-
sive molecular subtype in the progression tumor, or just
prior to it. This is exempliﬁed by the patient in Figure 5c,
showing a shift from papillary, UroA tumors to a muscle-
invasive, Neuroendocrine-like, progression tumor with loss
of RB1 and altered p53-pattern. The same TERT mutation
present in tumors 2–3 remained present in the progression
tumor, but the inferred ERBB2 ampliﬁcation status changed.
Differential gene expression in early vs. late tumors is
limited to molecular subtype shifts
To investigate systematic changes in gene expression over the
disease course, we performed pairwise comparisons between pri-
mary tumors (n = 42) and matched subsequent recurrences, and
between progression tumors (n = 33) and matched previous
recurrences. The analyses identiﬁed 135 and 239 differentially
expressed genes (DEGs; q < 0.01), respectively (Supporting
Information Table S7). Of 135 DEGs between primary tumors
and recurrences, 109 were upregulated in recurrences. These
genes were mainly coding for extracellular matrix (ECM) com-
ponents and markers of mesenchymal cells (Fig. 6a). A likely
explanation for this is that recurrences, when sampled, contain a
higher proportion of stroma. The 28 DEGs that were down-
regulated upon ﬁrst recurrence did not demonstrate any obvious
unifying biological theme. Comparison of progression tumors to
the last prior recurrence, identiﬁed 123 upregulated and
116 downregulated DEGs. Once again, the upregulated genes
were mainly coding for ECM components (e.g., FN1, COL1A1),
but also ECM remodeling enzymes (e.g., MMP11, ADAMTS2)
or blood vessel markers (e.g., SULF1, VCAN), suggesting that
either sample composition or the more invasive nature of pro-
gression tumors, may underlie these differences. Finally, the top
Figure 5. Progression tumors are either identical to previous recurrences or undergo subtype shifts. A summary of clinicopathological data,
molecular subtype, mutations, p53-status and inferred copy number data is shown in (a) ordered by patient, then by tumor number. For
inferred copy number alterations, blue boxes indicate gene expression proﬁles consistent with loss, and red boxes indicate proﬁle consistent
with ampliﬁcation. For CDKN2A, CCND1, RB1 and ERBB2, tumors with IHC-validated inferred copy number status is indicated with dark blue/
dark red boxes. (b) Three NMI tumors and the progression tumor from patient 6 show identical molecular proﬁle, including FGFR3
overexpression, FGFR3 mutation, TERT mutation and inferred MDM2 ampliﬁcation. (c) Three NMI tumors from patient 57 show radically shifted
proﬁles compared to the progression tumor. The NMI tumors are all TaG2 UroA tumors with ERBB2 overexpression, and TERT mutation
detected in the recurrences but not the primary. The progression tumor is T2G3 of Sc/NE subtype with identical TERT mutation, but with
molecular changes including RB1 loss, altered p53-pattern and absence of ERBB2 overexpression. [Color ﬁgure can be viewed at
wileyonlinelibrary.com]
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Figure 6. Differential gene expression between primary tumors, recurrences and progression tumors suggests stochastic or punctuated rather
than gradual modes of progression. Heatmap in (a) (left) showing expression in the full data set of 135 genes differentially expressed
between primary tumors and subsequent recurrences. Genes upregulated in recurrences formed a coherent signature and were mainly coding
for ECM components (LUM, DCN) and markers of nonepithelial cells (ZEB2, VIM). Heatmap in (a) (right) showing expression in the full data
set of 239 genes differentially expressed between the last NMI recurrences and subsequent progression tumors. Genes upregulated in
progression tumors formed a coherent signature and were mainly coding for ECM components (FN1, COL1A1) and genes involved in ECM
remodeling and invasion (MMP11, ADAMTS2). The top downregulated genes in progression tumors were members of a urothelial
differentiation signature expressed in luminal-like subtypes (SPINK1, HPGD, HMGCS2 and UPK1A). Ordering by molecular subtype, revealed
such downregulation primarily in nonluminal-like tumors and the same analysis, limited to patients with stable Urothelial-like subtype (UroA,
light green, UroB, brown or UroC, dark green) resulted in no signiﬁcant DEGs. (b) Schematic model suggesting different modes of progression
in bladder cancer: In the stable modality (ﬁrst and second panels), patients recur and progress stably within the Uro subtype (green color) or
the GU subtype (blue color), suggesting a common origin of all recurrences in a premalignant ﬁeld that only produces tumors of one subtype.
In the unstable modality (third and fourth panels), patients either develop both Uro or GU recurrences and progress with a GU subtype, or
progress to a nonluminal-like subtype (orange color, bottom). Patients that progress with a nonluminal-like subtype had few prior recurrences
that could be of any subtype (gray). The unstable modality of progression involves radical shifts in molecular subtype over the disease
course suggesting an underlying premalignant ﬁeld that is either heterogeneous or evolving to gives rise to various subtypes. [Color ﬁgure
can be viewed at wileyonlinelibrary.com]
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DEGs downregulated in progression tumors included multiple
members (SPINK1, HPGD, UPK1A and HMGCS2) of the core
urothelial differentiation signature that distinguish luminal-like
subtypes (Uro and GU) from their nonluminal counterparts
(Ba/Sq, MEs-like or Sc/NE). Thus, we observed two strong dif-
ferences in the gene expression proﬁle of progression tumors
compared to prior recurrences: an upregulation of ECM- or
blood vessel-related genes, and a downregulation of urothelial
differentiation signature genes. To determine if the DEGs are
driven by a gradual increase in aggressiveness or by a fraction of
progression tumors abruptly shifting over to nonluminal-like
subtypes, we limited the analyses to include only patients with
stable Uro tumors in Figure 3a. This resulted in no signiﬁcant
DEGs for either of the two pairwise analyses. Thus, progressed
tumors without a radical subtype shift did not show any system-
atic changes in gene expression, and the global differences in the
initial analysis of progression tumors were driven by the patients
that changed molecular subtype upon progression.
Discussion
Nonmuscle invasive bladder cancer (NMIBC) is a unique disease
in that multiple tumors can be diagnosed and removed allowing
longitudinal sampling from the same patient. We did not have
data on tumor location within the bladder, but since NMIBCs
usually recur in different locations,13 we assumed that each re-
section was complete and each tumor was independent in this
sense. Since our aim was to study patients longitudinally, data on
multifocality was not collected and all analyses were done on one
selected TUR-BT block. While the prognosis of NMIBC is com-
paratively good, it is not considered a benign condition, since a
proportion of patients progress to muscle-invasive or metastatic
disease despite intravesical treatment with BCG.36
Several observations prompted us to conduct our study. First,
it is not known to what extent the premalignant ﬁeld that gives
rise to recurrent NMIBC is genetically heterogeneous or oligo-
clonal. Such a genetic heterogeneity has been found in the pre-
malignant lesions in Barrett’s esophagus,5 and has been linked
to progression of breast tumors.37 The most detailed genetic
studies of the premalignant urothelium has been done in
research groups of Dyrskjøt,8,9 and Czerniak.6,7 Both groups
have used multiregion sampling from whole organs to identify
tumor-associated mutations in the noncancerous epithelium.
Thomsen et al. identify such mutations at low allele-frequency
suggesting spatial intermixing of the premalignant ﬁeld(s) with
wild-type urothelium.9 Several studies have also focused on
multifocal or recurrent NMIBC and somatic events, for exam-
ple, loss of heterozygosity (LOH) on chromosome 9 or FGFR3
mutation. Hartmann and colleagues showed that early
multifocal tumors are either identical, or different but compati-
ble with clonal origin.38 Van Tilborg and colleagues constructed
hierarchical relationships between NMIBC recurrences using
LOH patterns. Their analysis suggested that recurrences are
clonal but show a genetic timeline of tumors that did not match
their temporal order.11 Kompier and colleagues demonstrated
that FGFR3 mutations occur with relative stability in some
patients but not in others.18 Lindgren and colleagues used sev-
eral methods to describe remarkably similar molecular proﬁles
across recurrences.39 In general, our observations were consis-
tent with these studies, with minor differences which could be
explained by our selection of patients with progressive disease.
For example, the larger proportion of FGFR3 wild type tumors
in our study can be explained by such selection bias, since
FGFR3 mutation is associated with improved progression-free
survival in NMIBC.40,41 The frequency of FGFR3, PIK3CA, and
TERT mutations was comparable to previous studies on
NMIBC42,43 albeit with slight differences attributable to patient
selection. Since we studied only progressive disease, it also seems
logical that the variability between patients in, for example,
mutation instability is larger than in previous recurrence studies.
Still, some patients did show the extreme stability previously
reported for recurrences, but others had seemingly independent
events in each tumor. A limitation regarding the observed muta-
tion patterns is that they were based only on three genes, and
were partly based on negative results (wild type), which depend
on the assay sensitivity. Furthermore, to test whether within
patient stability correlates with genetically clonal/stable vs.
genetically oligo-clonal/unstable premalignant ﬁelds would
require sampling multiple recurrences and several biopsies from
normal-appearing urothelium at each time point.
A strength of our study compared to similar previous studies
is that we have access to an additional layer of phenotypic data
in molecular subtypes. The vast majority (IHC: 92% and mRNA:
87%) of this cohort was classiﬁed as “luminal-like” subtypes Uro
or GU, which in more advanced stages make up only about
50%.28,30,44 The dynamics of molecular subtypes in the cohort
was interesting: Patients that progressed with the Uro subtype
tended to have only prior Uro tumors; patients that progressed
with the GU subtype, tended to have either Uro or GU prior
tumors; and patient that progressed with nonluminal subtypes
had few prior tumors that could be of any subtype. These data
explain to some degree why certain subtypes are more frequent
at different disease stages. We studied closely the patients that
changed molecular subtype, and we could show that true
changes in molecular subtype are relatively rare and do not
coincide with changes in driver mutations. Instead, subtype
change may coincide to some degree with BCG treatment. This
hypothesis-generating ﬁnding remains unresolved since our data
were hampered by missing data from tumors just prior to, or
after BCG-treatment, which limited the power of the analysis.
Furthermore, our analysis of co-occurrence between subtype
shifts and BCG made use of all tumors, even those that clinically
might not have been candidates for BCG, further limiting the
conclusions of this analysis. The positive co-occurrence of sub-
type change and p53-alteration in recurrences was more robust.
This suggests that for patients who progress from a Uro subtype
(with low TP53 mutation frequency) to a more aggressive sub-
type, the “progressed” invasive tumors have similar TP53 muta-
tion frequency as de novo muscle-invasive cases among those
10 Molecular changes in bladder cancer progression
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subtypes. Note that we deﬁne a subtype change as the consecu-
tive observation of two different molecular subtypes within one
patient. It is not possible to read out from these data whether
the molecular subtype of one lesion has changed, or whether the
two subtypes have evolved in parallel.
Our analysis of gene expression in regions of copy-number
alterations showed that the rough inference of genetic events
from gene expression data was largely conﬁrmed at the protein
level. Inferred alterations seemed more stable within patients
than driver mutations. Previous studies have indicated that
homozygous deletions of CDKN2A, a hallmark of advanced Uro
tumors, correlate with progression and occur late in develop-
ment.45 We did not observe this pattern, possibly due to difﬁculty
to discriminate homozygous loss from single-copy loss of chro-
mosome 9, a universal event also in very early bladder
tumors.42,46 To deﬁnitively test the accuracy of inferring copy
number alterations would require copy-number data from a sim-
ilar series of recurrences, which was not possible due to the qual-
ity and amount of DNA obtained. If the validity of this approach
can be established, copy number alterations inferred by patterns
of RNA abundance may be an efﬁcient way to study similarity
between NMIBC recurrences and premalignant urothelium.
The early division between Uro and GU subtypes often per-
sisted over multiple recurrences, which is in line with the mutu-
ally exclusive nature of these subtypes in a recent study on UBC
and concomitant histologic variants.47 The two entities Uro and
GU, identiﬁed by unsupervised clustering of RNA proﬁles, mirror
the marker proﬁles of hyperplasia and carcinoma in situ, respec-
tively.48 The molecular subtypes, therefore, provide a phenotypic
correlate to the well-established “two pathway model” of bladder
tumorigenesis that is rooted in histology and genetics.39,49,50
Taken together, our data is fully compatible with a model in
which a clonal premalignant ﬁeld is the precursor of semi-
independent recurrences. However, recent work has demon-
strated the similarity between upper urinary tract urothelial
cancer and bladder recurrences suggesting that recurrence due
to dissemination may occur in this particular context.51 By
introducing the concept of molecular subtypes, we contextual-
ize also the well-established two-pathway model for luminal-
like tumors. Finally, we add to the model two fundamentally
different modes of progression: For most patients, progression
occurs without any change in molecular subtype. Most often,
the premalignant ﬁeld only gives rise to Uro tumors (Fig. 6b,
top). These progression tumors have no DEGs, or other sys-
tematic molecular changes compared to earlier recurrences.
Less frequently, patients may also recur with GU tumor only
(Fig. 6b, second panel). In its other modality, progression is
coupled to an abrupt subtype change suggesting that ﬁeld het-
erogeneity, possibly caused by genomic instability within the
ﬁeld, could produce tumors of different molecular subtypes.
For Uro to GU transitions (Fig. 6b, third panel) this manifests
in upregulated invasion related genes, and for patients
transitioning to nonluminal subtypes (Fig. 6b, bottom) it also
involves downregulation of urothelial differentiation genes.
Both the two last scenarios involve subtype change and may
also coincide with acquiring abnormal p53 staining pattern
indicative of TP53 mutation. We note that our suggested
“punctuated” progression model is incompatible with the con-
cept of gradual increases in aggressiveness culminating in inva-
sion and clinical progression. Instead, we suggest that radical
changes, when observed in overt tumors, are manifestations of
a “sea change”, or instability, in the premalignant precursor
ﬁeld enabling it to (also) produce tumors of a new type.
The majority of patients, however, progress with the ﬁrst
type, that is, stable Uro disease. These patients will likely be
difﬁcult to identify at baseline from patients with Uro recur-
rences that never progress. The difference may even be sto-
chastic, that is, stable Uro patients that progress may be
impossible to separate from those that do not. Another possi-
bility is that factors already present at tumor initiation specify
recurrence and progression risk individually for each patient.
Since all tumors from stable Uro patients are similar, any
tumor may serve as a representative index tumor for that
patient. The second group of patients has opposite behavior
with drastic changes in molecular proﬁles before or during
progression. A robust change in molecular subtype or an
occurrence of NMIBC with nonluminal subtype would indi-
cate a patient may be of this type. For such patients, risk-
prediction based on biomarkers from a single index tumor
will be inadequate since they represent only one of many
molecular manifestations possible in the patient’s bladder.
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